Lexeo Therapeutics, Inc.
LXEO Nasdaq· Biological Products, (No Diagnostic Substances)
Last close · Oct 26, 2026
$2.70
KIRA · Stoqly’s AI analyst, in plain words
- Lexeo Therapeutics, Inc. lost $100M in fiscal 2025.
- Free cash flow was −$99.0M in fiscal 2025, — of revenue.
Market cap
$231M
P/E
—
Revenue
—
Net income
−$100M
Free cash flow
−$99.0M
Operating margin
—
Lexeo Therapeutics, Inc. in 30 seconds · fiscal 2025
Does it make a profit?
−$100M
No. It lost money last year.
How is the share priced?
—
No P/E: it made no profit over the last four quarters.
What Lexeo Therapeutics, Inc. does
No business description yet.
- Fiscal year ends
- December 31, 2025
- Latest annual report
- 10-K · Mar 30, 2026
- Legal name
- Lexeo Therapeutics, Inc.
- CIK
- 0001907108
Lexeo Therapeutics, Inc. · LXEO
Results and finances
The last 4 fiscal years. Amounts in USD.
| Fiscal year | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|
| Sales and profit | ||||
| Revenue | $0.7M | — | — | — |
| Operating margin | −9,252.1% | — | — | — |
| Net income | −$59.3M | −$66.4M | −$98.3M | −$100M |
| Net margin | −9,063.8% | — | — | — |
| Diluted EPS | −$36.36 | −$12.40 | −$3.09 | −$1.86 |
| Cash | ||||
| Cash from operations | −$54.6M | −$59.5M | −$81.2M | −$98.6M |
| Capital expenditure | $0.7M | $0.1M | $0.5M | $0.4M |
| Free cash flow | −$55.2M | −$59.6M | −$81.6M | −$99.0M |
| FCF margin | −8,445.3% | — | — | — |
| Share count change | — | 228.4% | 493.7% | 68.8% |
| Debt and strength | ||||
| Cash and short-term investments | $77.3M | $121M | $122M | $182M |
| Shareholders' equity | −$113M | $114M | $117M | $247M |
| Current ratio | 5.6x | 7.2x | 5.5x | 11.2x |
| Interest coverage | −664.9x | −334.2x | −772.0x | −1,150.1x |
| Returns and quality | ||||
| Return on equity | — | −22,855.1% | −85.4% | −55.0% |
| Return on tangible equity | — | −58.5% | −84.2% | −40.5% |
| Altman Z'' | −8.4 | 2.0 | −2.4 | 8.6 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.7M
7 insiders
Of sales under plans
42%
$0.3M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Lexeo Therapeutics, Inc. · LXEO
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $2.70 a share, the company is worth $231M.
Source: SEC EDGAR XBRL filings (CIK 0001907108). Data updated October 24, 2026. For information only — not investment advice. Check the original filings before relying on any figure.